Gilead to Acquire CymaBay Therapeutics and its Liver Disease Drug for US$4.3 B
By Lucy Haggerty
Pharma Deals Review: Vol 2024 Issue 3 (Table of Contents)
Published: 2 Mar-2024
DOI: 10.3833/pdr.v2024.i3.2855 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to bolster its liver portfolio, Gilead Sciences has agreed to acquire CymaBay Therapeutics for US$32...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS